Izotropic Corporation has revised its exclusive global licensing agreement with UC Davis for its breast cancer imaging technology. The amended agreement aligns with Izotropic's strategic plans for the IzoView Breast CT Imaging System and future imaging products. The company maintains exclusive worldwide rights to develop, manufacture, and market Breast CT and related technologies from UC Davis Medical Center. The revised terms require Izotropic to obtain either U.S. FDA approval or foreign equivalent certification (like CE Mark), begin marketing, and achieve first commercial sale within specified timeframes that match their U.S. product launch timeline. The agreement includes sublicensing rights for global commercialization and requires a diligence obligation fee of USD $85,000, payable in installments by November 2025.
Izotropic Corporation ha rivisto il suo accordo esclusivo di licenza globale con UC Davis per la tecnologia di imaging del cancro al seno. L'accordo modificato 猫 in linea con i piani strategici di Izotropic per il sistema di imaging IzoView Breast CT e per i futuri prodotti di imaging. L'azienda mantiene i diritti esclusivi a livello mondiale per sviluppare, produrre e commercializzare la tecnologia Breast CT e tecnologie correlate provenienti dal UC Davis Medical Center. I termini rivisti richiedono a Izotropic di ottenere l'approvazione FDA statunitense o una certificazione equivalente estera (come il marchio CE), iniziare la commercializzazione e realizzare la prima vendita commerciale entro scadenze specifiche che corrispondono alla tempistica di lancio del prodotto negli Stati Uniti. L'accordo include diritti di sublicenza per la commercializzazione globale e prevede un canone di obbligo di diligenza di 85.000 USD, pagabile in rate entro novembre 2025.
Izotropic Corporation ha revisado su acuerdo exclusivo de licencia global con UC Davis para su tecnolog铆a de imagenolog铆a del c谩ncer de mama. El acuerdo enmendado se alinea con los planes estrat茅gicos de Izotropic para el sistema de imagen IzoView Breast CT y futuros productos de imagen. La compa帽铆a mantiene los derechos exclusivos mundiales para desarrollar, fabricar y comercializar Breast CT y tecnolog铆as relacionadas del UC Davis Medical Center. Los t茅rminos revisados requieren que Izotropic obtenga la aprobaci贸n de la FDA de EE.UU. o una certificaci贸n equivalente extranjera (como la marca CE), comience la comercializaci贸n y logre la primera venta comercial dentro de los plazos especificados que coinciden con el calendario de lanzamiento del producto en EE.UU. El acuerdo incluye derechos de sublicencia para la comercializaci贸n global y requiere una cuota de diligencia de 85,000 USD, pagadera en cuotas antes de noviembre de 2025.
Izotropic Corporation a r茅vis茅 son accord exclusif mondial de licence avec UC Davis pour sa technologie d'imagerie du cancer du sein. L'accord amend茅 s'aligne sur les plans strat茅giques d'Izotropic pour le syst猫me d'imagerie IzoView Breast CT et les futurs produits d'imagerie. La soci茅t茅 conserve les droits exclusifs mondiaux pour d茅velopper, fabriquer et commercialiser la technologie Breast CT et les technologies connexes du UC Davis Medical Center. Les termes r茅vis茅s exigent qu'Izotropic obtienne soit l'approbation de la FDA am茅ricaine, soit une certification 茅quivalente 茅trang猫re (comme le marquage CE), commence la commercialisation et r茅alise la premi猫re vente commerciale dans des d茅lais sp茅cifi茅s correspondant au calendrier de lancement du produit aux 脡tats-Unis. L'accord inclut des droits de sous-licence pour la commercialisation mondiale et requiert des frais d'obligation de diligence de 85 000 USD, payables en plusieurs versements d'ici novembre 2025.
Die Izotropic Corporation hat ihre exklusive globale Lizenzvereinbarung mit UC Davis f眉r ihre Brustkrebs-Bildgebungstechnologie 眉berarbeitet. Die ge盲nderte Vereinbarung entspricht den strategischen Pl盲nen von Izotropic f眉r das IzoView Breast CT Imaging System und zuk眉nftige Bildgebungsprodukte. Das Unternehmen beh盲lt die exklusiven weltweiten Rechte zur Entwicklung, Herstellung und Vermarktung von Breast CT und verwandten Technologien des UC Davis Medical Center. Die 眉berarbeiteten Bedingungen verlangen von Izotropic, entweder eine FDA-Zulassung der USA oder eine ausl盲ndische gleichwertige Zertifizierung (wie CE-Kennzeichnung) zu erhalten, mit dem Marketing zu beginnen und den ersten kommerziellen Verkauf innerhalb festgelegter Fristen zu t盲tigen, die mit dem US-Produktstartzeitplan 眉bereinstimmen. Die Vereinbarung beinhaltet Unterlizenzrechte f眉r die globale Kommerzialisierung und erfordert eine Verpflichtungsgeb眉hr von 85.000 USD, zahlbar in Raten bis November 2025.
Positive
Exclusive worldwide licensing rights for Breast CT and related technologies
Flexibility for global market entry through sublicensing rights
Agreement revision aligns with company's strategic plans and product launch timeline
Potential for multiple revenue streams through sales, distribution fees, and pay-per-use fees
Negative
Additional financial obligation of USD $85,000 due by November 2025
Strict regulatory approval and commercialization deadlines must be met to maintain licensing rights
- License agreement enables U.S. FDA approval or foreign equivalent (CE mark) - - Amendment aligns with Company's timelines for IzoView product launch - - Agreement amendment fees of USD $85K payable in installments -
Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - June 10, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a medical device company commercializing imaging-based products utilizing innovative and emerging technologies for the more accurate screening, diagnoses, and treatment of breast cancers, is pleased to announce that it has revised its exclusive global licensing agreement with the Regents of the University of California ("UC Davis") to align with the Company's current strategic positioning, , and global commercialization plans for the ("IzoView"), and other planned imaging-based products.
Izotropic holds the exclusive worldwide licensing rights to Breast CT and other technologies, patents, and patent applications developed at UC Davis Medical Center, in Sacramento, California. The agreement positions Izotropic as the sole commercial entity with the rights to develop, manufacture, and market these innovations for human screening, diagnostic, and therapeutic (treatment) use. The license agreement includes sublicensing rights that the Company may utilize to commercialize imaging technologies in global business sectors in exchange for sales revenues, distribution fees, and/ or pay-per-use fees on all licensed products.
Under the terms of the revised agreement, Izotropic is required to achieve U.S. regulatory approval or that of a foreign equivalent (such as European CE Mark), initiate marketing, and achieve the first commercial sale by specified dates that align with, but are not limited to, the Company's timelines for the of IzoView. This structure offers flexibility for global market entry while ensuring licensing compliance for IzoView and enabling the advancement and commercialization of a more diversified portfolio of imaging technologies.
Izotropic has agreed to a diligence obligation fee of USD $85K due by November 2025, payable in structured installments.
About Izotropic: More information about Izotropic Corporation can be found on its website at and by reviewing its profile on SEDAR+ at .
Forward-Looking Statements: This document may contain statements that are "Forward-Looking Statements," which are based upon the current estimates, assumptions, projections, and expectations of the Company's management, business, and its knowledge of the relevant market and economic environment in which it operates. The Company has tried, where possible, to identify such information and statements by using words such as "anticipate," "believe," "envision," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," "contemplate" and other similar expressions and derivations thereof in connection with any discussion of future events, trends or prospects or future operating or financial performance, although not all forward-looking statements contain these identifying words.
These statements are not guarantees of performance and involve risks, including those related to capital requirements and uncertainties that are difficult to control or predict, and as such, they may cause future results of the Company's activity to differ significantly from the content and implications of such statements. Forward-Looking Statements are pertinent only as of the date on which they are made, and the Company undertakes no obligation to update or revise any Forward-Looking Statements to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law. Neither the Company nor its shareholders, officers, and consultants shall be liable for any action and the results of any action taken by any person based on the information contained herein, including, without limitation, the purchase or sale of Company securities. Nothing in this document should be deemed to be medical or other advice of any kind. All images are for illustrative purposes only. IzoView has not yet been approved or cleared for sale.
Contacts: Robert Thast, Interim Chief Executive Officer Telephone: 1-604-220-5031 or 1-833-IZOCORP ext. 1 Email: [email protected]
James Gagnon, International Communications Telephone: 1-604-780-7576 or 1-833-IZOCORP ext. 2
General and Corporate Inquiries Telephone: 1-604-825-4778 or 1-833-IZOCORP ext. 3 Email: [email protected]
To view the source version of this press release, please visit
FAQ
What are the key terms of IZOZF's revised license agreement with UC Davis?
The agreement grants Izotropic exclusive worldwide rights to develop, manufacture, and market Breast CT technology, requiring FDA or foreign equivalent approval, marketing initiation, and first commercial sale by specified dates, with an $85,000 diligence fee due by November 2025.
How much will Izotropic pay for the license agreement amendment?
Izotropic will pay a diligence obligation fee of USD $85,000, payable in structured installments by November 2025.
What products are covered under Izotropic's license agreement with UC Davis?
The agreement covers the IzoView Breast CT Imaging System and other imaging-based products developed at UC Davis Medical Center for breast cancer screening, diagnosis, and treatment.
What regulatory approvals does IZOZF need under the revised agreement?
Izotropic needs to obtain either U.S. FDA approval or a foreign equivalent certification, such as European CE Mark, for their products.
What commercial rights does the license agreement give to Izotropic?
The agreement gives Izotropic exclusive worldwide rights to develop, manufacture, and market the technologies, including sublicensing rights for global commercialization in exchange for sales revenues, distribution fees, and pay-per-use fees.
An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, to receive support.
